Azenta Life Sciences Partners with PRECEDE Foundation to Advance Early Detection of Pancreatic Cancer
Azenta (Nasdaq: AZTA) announced a strategic partnership with the PRECEDE Foundation on Nov 4, 2025 to support early detection of pancreatic cancer by providing secure biorepository storage and streamlined logistics for PRECEDE study samples.
PRECEDE unites more than 60 academic medical centers and maintains the world's largest high-risk patient cohort combining longitudinal clinical data with biospecimen tracking. Pancreatic cancer currently has a five-year survival rate of 13%, and PRECEDE's stated goal is to raise that to 50% within the next decade. Azenta frames the agreement as reinforcing its position in sample management for clinical and diagnostic research and will support PRECEDE ahead of its Annual Meeting in November.
Azenta (Nasdaq: AZTA) ha annunciato una partnership strategica con la PRECEDE Foundation il 4 novembre 2025 per supportare l'individuazione precoce del cancro al pancreas fornendo la conservazione sicura della biobanca e una logistica snella per i campioni dello studio PRECEDE.
PRECEDE riunisce oltre 60 centri medici accademici e mantiene il più grande coorte di pazienti ad alto rischio al mondo, combinando dati clinici longitudinali con il tracciamento dei campioni biologici. Il cancro al pancreas attualmente ha un tasso di sopravvivenza a cinque anni del 13%, e l'obiettivo dichiarato di PRECEDE è aumentarlo al 50% entro il prossimo decennio. Azenta inquadra l'accordo come un rafforzamento della sua posizione nel management dei campioni per la ricerca clinica e diagnostica e sosterrà PRECEDE prima della sua Assemblea Annuale di novembre.
Azenta (Nasdaq: AZTA) anunció una asociación estratégica con la PRECEDE Foundation el 4 de noviembre de 2025 para apoyar la detección temprana del cáncer de páncreas proporcionando almacenamiento seguro de biobancos y logística simplificada para las muestras del estudio PRECEDE.
PRECEDE reúne a más de 60 centros médicos académicos y mantiene la mayor cohorte de pacientes de alto riesgo del mundo, combinando datos clínicos longitudinales con el seguimiento de biospecímenes. El cáncer de páncreas tiene actualmente una tasa de supervivencia a cinco años del 13%, y el objetivo declarado de PRECEDE es aumentarla al 50% dentro de la próxima década. Azenta enmarca el acuerdo como un fortalecimiento de su posición en la gestión de muestras para la investigación clínica y diagnóstica y apoyará a PRECEDE antes de su Reunión Anual en noviembre.
Azenta (나스닥: AZTA)는 PRECEDE 재단과 2025년 11월 4일 전략적 파트너십을 발표했습니다. 이는 PRECEDE 연구 샘플의 보관을 안전하게 하고 샘플의 물류를 간소화하여 췌장암의 조기 발견을 지원하기 위한 것입니다.
PRECEDE는 60개 이상의 학술 의과센터를 연합하고 세계에서 가장 큰 고위험 환자 코호트를 보유하며, 종단적 임상 데이터와 생체시료 추적을 결합합니다. 췌장암의 현재 5년 생존률은 13%이며 PRECEDE의 목표는 이를 향후 10년 내에 50%로 올리는 것입니다. Azenta는 이 협정을 임상 및 진단 연구를 위한 샘플 관리에서 자사의 위치를 강화하는 것으로 해석하며, 11월 연례회의를 앞두고 PRECEDE를 지원할 것입니다.
Azenta (Nasdaq : AZTA) a annoncé le 4 novembre 2025 un partenariat stratégique avec la PRECEDE Foundation pour soutenir le dépistage précoce du cancer du pancréas en fournissant un stockage sécurisé en biobanque et une logistique rationalisée pour les échantillons de l'étude PRECEDE.
PRECEDE réunit plus de 60 centres médicaux universitaires et possède la plus grande cohorte de patients à haut risque au monde, combinant des données cliniques longitudinales avec le suivi des biospécimens. Le cancer du pancréas présente actuellement un Taux de survie à cinq ans de 13%, et l'objectif déclaré de PRECEDE est de l'élever à 50% d'ici la prochaine décennie. Azenta présente cet accord comme le renforcement de sa position dans la gestion des échantillons pour la recherche clinique et diagnostique et soutiendra PRECEDE avant sa Réunion annuelle de novembre.
Azenta (Nasdaq: AZTA) hat am 4. November 2025 eine strategische Partnerschaft mit der PRECEDE Foundation angekündigt, um die Früherkennung von Bauchspeicheldrüsenkrebs zu unterstützen, indem sichere Biobank-Speicherungen und eine optimierte Logistik für PRECEDE-Studienproben bereitgestellt werden.
PRECEDE vereint mehr als 60 akademische medizinische Zentren und führt die weltweit größte Hochrisiko-Patientenkohorte, die longitudinale klinische Daten mit der Verfolgung von Biospecimens kombiniert. Bauchspeicheldrüsenkrebs hat derzeit eine fünfjährige Überlebensrate von 13%, und das erklärte Ziel von PRECEDE ist es, diese bis zu 50% innerhalb des nächsten Jahrzehnts zu erhöhen. Azenta sieht die Vereinbarung als Stärkung seiner Position im Probenmanagement für klinische und diagnostische Forschung und wird PRECEDE vor der Jahresversammlung im November unterstützen.
أزنتا (ناسداك: AZTA) أعلنت عن شراكة استراتيجية مع مؤسسة PRECEDE في 4 نوفمبر 2025 لدعم الكشف المبكر عن سرطان البنكرياس من خلال توفير تخزين آمن لمخازن العينات الحيوية وتسهيل اللوجستيات لعينات دراسة PRECEDE.
PRECEDE تجمع أكثر من 60 مركزاً طبياً أكاديمياً وتحافظ على أكبر تجمع لمرضى عاليي المخاطر في العالم، يجمع بين بيانات سريرية طولية وتتبع العينات البيولوجية. سرطان البنكرياس حالياً لديه معدل بقاء على قيد الحياة لمدة خمس سنوات يبلغ 13%، والهدف المعلن لـ PRECEDE هو رفعه إلى 50% خلال العقد القادم. يرى أزنتا أن الاتفاق يعزز موقعها في إدارة العينة للبحوث السريرية والتقييم تشخيصي وسيؤيد PRECEDE قبل اجتماعها السنوي في نوفمبر.
- Partnership to store and manage PRECEDE study samples
- Access to PRECEDE's cohort spanning >60 academic medical centers
- Supports the world's largest high-risk pancreatic cancer cohort
- No financial terms or revenue impact disclosed
Insights
Azenta provides biorepository and logistics services to PRECEDE to support large-scale pancreatic cancer early‑detection research.
Azenta will store and manage PRECEDE Foundation's study samples and handle logistics, preserving longitudinal biospecimens for more than 60 academic sites. The partnership aligns Azenta's repository services with PRECEDE's mission to improve screening and risk modeling for individuals at hereditary risk of pancreatic cancer. The release cites a five‑year survival rate of
Operationally, this agreement reduces sample‑handling burden for researchers and centralizes chain‑of‑custody and quality control under Azenta's global sample management. Key dependencies include uninterrupted biorepository operations and secure logistics to maintain sample integrity. Watch for progress updates at the PRECEDE Annual Meeting in
Pancreatic cancer is the third-leading cause of cancer-related deaths in
PRECEDE, the Pancreatic Cancer Early Detection Consortium, was established to change this trajectory. Its mission is to improve screening, risk modeling, and prevention for individuals with a hereditary risk of developing pancreatic cancer, with the ambitious goal of increasing the five-year survival rate from
"Early detection is the key to survival in pancreatic cancer," said Kathi Shea, Chief Client Solutions Officer, Repository at Azenta. "We're proud to support PRECEDE's groundbreaking work by safeguarding and managing their critical samples in our biorepository, helping ensure the continuity of their research every step of the way. Through this partnership, Azenta is helping to drive the development of tools and strategies for earlier diagnosis, with the potential to save thousands of lives each year. This partnership highlights Azenta's strategic role in the growing biorepository resources for the clinical and diagnostic research market, reinforcing its position as a trusted partner for high-impact life science research."
Azenta's global expertise in sample management ensures the quality and continuity needed to support PRECEDE's mission, allowing researchers to focus fully on discovery and innovation.
The PRECEDE Foundation will host its Annual Meeting in November, where international experts will convene to share progress and further collaborative strategies. To learn more about the Foundation's mission and ongoing work, please visit www.precedefoundation.org.
About PRECEDE Consortium
The PRECEDE Consortium is an international, multi-institutional collaborative group of experts and industry partners whose mission is to increase survival for pancreatic cancer patients.
With over 60 leading academic medical centers across the globe, the PRECEDE Consortium has assembled the largest high-risk patient cohort, with longitudinal clinical data and biospecimen acquisition and tracking, and the leading clinicians and scientists in their field. The Consortium also brings cutting-edge technologies to advance the ability to detect pancreatic cancer at its earliest stages.
About PRECEDE Foundation
The PRECEDE Foundation is the fundraising and infrastructure organization supporting PRECEDE. The Foundation's sole mission is to raise the funds and awareness necessary to aid PRECEDE's goals to increase the survival rate of pancreatic cancer through early detection.
About Azenta Life Sciences
Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling life science organizations around the world to bring impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. Our global team delivers and supports these products and services through our industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey.
Azenta is headquartered in
MEDIA CONTACT for PRECEDE Foundation:
Jessica Forres
jessica@ekkopr.com
INVESTOR CONTACT for Azenta Life Sciences:
Yvonne Perron
Vice President, Financial Planning & Analysis, and Investor Relations
ir@azenta.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/azenta-life-sciences-partners-with-precede-foundation-to-advance-early-detection-of-pancreatic-cancer-302604661.html
SOURCE Azenta
FAQ
What did Azenta (AZTA) announce on Nov 4, 2025 regarding pancreatic cancer research?
How many institutions are involved in the PRECEDE cohort supported by AZTA?
What survival-rate goal did PRECEDE set that AZTA will support on Nov 4, 2025?
Will the Azenta–PRECEDE partnership have immediate revenue impact for AZTA?
When will PRECEDE convene experts to share progress that AZTA will support?
